DYAI Stock Analysis
DY
Uncovered
Dyadic International Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 7 full-time employees. The company went IPO on 2004-11-05. The firm is focused on developing biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (C1) for use in human and animal pharmaceutical applications across the world. The C1-cell protein production platform is a robust and versatile thermophilic filamentous fungal expression system for the development and production of biologic products including enzymes and other proteins. The firm is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. In addition, the Company is also focused on developing other technologies that have applications in non-pharmaceutical markets.